Search results
Author(s):
Walid Saliba
Added:
3 months ago
AF Symposium 25 - Left atrial appendage (LAA) closure using the WATCHMAN FLX device (Boston Scientific) showed lower risk of bleeding and non-inferiority in efficacy endpoints to oral anticoagulation in patients who have received or are planning to receive AF ablation.Dr Walid Saliba (Cleveland Clinic, OH, US) joins us onsite at AF Symposium 25 to discuss the findings from the concomitant and…
View more
Author(s):
Paulus Kirchhof
Added:
1 year ago
ESC 2023 — Prof Paulus Kirchhof (University Heart & Vascular Center Hamburg, DE) discusses the findings of the NOAH-AFNET 6 trial (NCT02618577).
NOAH-AFNET 6 (Atrial Fibrillation Network, Daiichi Sankyo Europe) was an investigator-initiated, prospective, randomised trial aiming to demonstrate that oral anticoagulation using the NOAC edoxaban is superior to current therapy in stroke prevention,…
View more
Author(s):
Julius Nikorowitsch
Added:
1 year ago
EHRA 24 - We are joined onsite by Dr Julius Nikorowitsch (University Heart and Vascular Centre Hamburg (UHZ), DE) to outline the impact of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation in a substudy of the NOAH-AFNET 6 trial (NCT02618577).The substudy consisted of 2534 patients from…
View more
Author(s):
Else Sandset
,
Jesse Dawson
,
Urs Fischer
,
et al
Added:
1 year ago
Dr Else Sandset (Oslo University Hospital, NO) is joined by Prof Jesse Dawson (University of Glasgow, GB), Dr Urs Fischer (University Hospital Basel, CH) and Dr Masatoshi Koga (National Cerebral and Cardiovascular Center, JP) to discuss the findings from their recent paper on "Early versus Later Anticoagulation for Stroke with Atrial Fibrillation" published in the New England Journal of Medicine…
View more
Hakan Oral
Research Area(s) / Expertise:
Author
Author(s):
Linda Joosten
Added:
1 year ago
ESC 2023 — Dr Linda Joosten (Julius Center for Health Sciences and Primary Care, NL) joins us to discuss the findings of the FRAIL-AF trial.
FRAIL-AF is a multicentre, open-label randomised controlled clinical trial which studied frail elderly patients who receive vitamin K antagonist (VKA) treatment for atrial fibrillation (AF). Current clinical guidelines recommend non-vitamin K antagonists …
View more
AF Symposium 2025 Late-Breaking Science Collection
Video Series
Ken Okumura
Research Area(s) / Expertise:
Author
AF Stroke Prevention
Video Series
Author(s):
Tim R Betts
,
Patrick A Calvert
,
Lee N Graham
,
et al
Added:
1 year ago